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Aims: Premature discontinuation of antiplatelet therapy has been iden-
tified as a major risk factor for stent thrombosis and prior aspirin
withdrawal has been associated with poor prognosis after acute coronary
syndrome. We investigated the hypothesis that biological aspirin “resis-
tance” may often be related to non compliance in patients undergoing
coronary stenting.
Methods and Results: We prospectively investigated the occurrence of
aspirin non compliance in 136 consecutive patients undergoing coronary
stenting receiving aspirin 75 mg daily. We analyzed post-treatment
maximal intensity of arachidonic acid-induced platelet aggregation (AA-
Ag) during hospitalization after controlled intake of aspirin and one month
after hospital discharge. After one month, all non responders received con-
trolled aspirin 75 mg and assessment of response was repeated. Aspirin
non response was defined by AA-Ag>30%. During in-hospital period, the
range of AA-Ag varied from 0 to 34% with a mean value of 7.5±10 % and
4 patients (3%) were classified as non responders. One month after dis-
charge, AA-Ag of the population was significantly higher than during the
hospital phase (15.3±23 vs 7.5±10%, p=0.0004) and 19 patients (14%)
were identified as non responders. After controlled administration of
aspirin, all but one of these “non responders” became responders and were
identified as patients with non compliance rather than biological resis-
tance.
Conclusion: Aspirin resistance is rare in compliant patients using methods
that directly indicate the degree of platelet cyclooxygenase inhibition. More
than 10% of patients receiving aspirin for coronary stenting are non compliant
for aspirin therapy during the first month after stenting. These results suggest
a need for improved education of these patients.
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Aim: In STEMI, controversial data exist on the relative importance of
patient-dependent time (Symptom-Onset (SO) to first medical contact (FMC))
and Transfer Time (TT=time from FMC to sheath insertion). We assessed the
impact of TT on in-hospital (IH) mortality in a well organized urban network
using Mobile Intensive Care Units (MICU).
Methods: In a web-based registry (e-PARIS), we evaluated delay in care
of 705 consecutive STEMI patients transferred to the Pitié-Salpêtrière cath-lab
for primary PCI.
Results: Population was 63±14 y/o, 75.6% were male, 46.9% had anterior
MI, 16.7% were in Killip class 2, and 3.8% had out-of-hospital cardiac arrest.
Abciximab was used in 82.4%, radial approach in 87.7% and stenting in
89.7% of patients. Median time (IQR) from SO to FMC was 110 (248) min
(102 (190) min when FMC was MICU and 160 (381) min when FMC was a
referring hospital, p<0.0001). Median TT was 104 (75) min (95 (45) min for
MICU and 151 (178 )min for patients transferred from a primary hospital,
p<0.0001). When divided into quartiles, increasing TT was associated with
higher IH mortality. This relation to IH mortality was striking in patients pre-
senting early (within 2 hours of SO), and not significant in late presenters (>2
hours of SO) (fig). After adjustment for baseline characteristics, TT was not
associated with mortality anymore suggesting that the sicker patients had the
longest TT.
Conclusions: The association between TT and early mortality is strongly
dependent on patients’ characteristics and time to presentation. After adjust-
ment for these parameters, TT does not appear to be a major contributor of IH
mortality in a well organized urban network for primary PCI. Improving time-
to-first medical contact may be more critical.
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Background: The *2 variant of the CYP2C19 gene encodes a defective
enzyme that likely fails to adequately convert clopidogrel to its active metabo-
lite, leading to diminished cardiovascular protection.
Objectives: We performed a meta-analysis of trials that determined the
CYP2C19*2 genetic variant in patients exposed to clopidogrel therapy after
stent implantation. The primary objective was to evaluate whether carriage of
the CYP2C19*2 was associated with the occurrence of stent thrombosis, recur-
rent myocardial infarction and cardiovascular death.
Methods and results: Eight trials (9427 patients) with data available data
on death, recurrent myocardial infarction, stent thrombosis and any ischemic
events were selected. The odds ratio (OR) as the parameter of efficacy with a
fixed effect model was used. Carriers of the genetic variant associated with a
loss-of-function of the CYP2C19 enzyme (28%, n=2674) displayed a 30%
increase in the risk in any ischemic events compared to non carriers (10.4% vs
8.3%) (OR, 1.31; 95% CI, 1.12-1.53; p<0.001). This metanalysis confirmed
the excess of stent thrombosis (2.9% vs 0.9%) (OR 3.01; 95% CI: 1.89-4.80,
p<0.001)(n=4975) but also of death or MI (12.1% vs 5.3%)(OR 2.51; 95% CI:
2.07-3.05, p<0.001)(n=7022). This single gene variant (CYP2C19*2) was also
associated with an excess of cardiovascular mortality (1.8% vs 1.0%)(OR
1.79; 95% CI: 1.10-2.91, p<0.019)(n=6225).
Conclusions: Our findings support rapid genetic testing for the
CYP2C19*2 to identify patients with a deficient clopidogrel metabolic activa-
tion. The clinical relevance of such approach remains to be established by ade-
quately powered randomized studies.
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 Purpose: The present observational study compares in-hospital and 12
month clinical outcomes in elderly patients (aged ≥ 75 years) with unprotected
left main coronary artery (ULMCA) disease treated either with coronary artery
bypass grafting (CABG) or drug eluting stent (DES).
Methods: From January 2004 to December 2007, 211 patients (pts) with
ULMCA stenosis, aged 75 or older, underwent a coronary revascularisation
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either with CABG (106 pts) or DES (105 pts). Decision to treat with CABG
or PCI was dependent on the patient’s and the physisican’s choice. The occur-
rence of major adverse cardiac or cerebrovascular events (MACCE: death, non
fatal myocardial infarction or stroke) and revascularisations was recorded after
one year follow-up. A multivariate logistic regression analysis was performed,
using a propensity score method to take into account potential baseline diffe-
rences between groups.
Results: In-hospital MACCE rates were 5.7% and 3.8% in CABG and PCI
groups, respectively (p=0.748). After, one-year follow-up, rates were respecti-
vely 15.4% and 16.3% (p=0.865). Rates for target vessel revascularisation at
12 months were 1.1% and 15.2% (p<0.001). PCI group was significantly asso-
ciated with older age, dyslipidaemia, history of cancer, high euroscore, ele-
vated creatininemia, single vessel disease, chronic occlusion of left anterior
descending artery and LMCA stenosis ≥70%. The multivariable logistic
regression analysis was adjusted for age, diabetes, left ventricular ejection
fraction, euroscore, and stratified on the propensity score to be treated with
PCI. In the subgroup below median propensity score, the adjusted odds ratio
for one-year MACCE was OR=0.98 (95% confidence interval: 0.17 to 5.67;
p=0.981) whereas OR was 0.20 (0.04 to 0.97; p=0.046) in the subgroup above
median propensity score.
Conclusions: In patients with a high probability to be treated with PCI
(older age, high euroscore, high creatininemia, single vessel disease…), one-
year risk of death was significantly lower in PCI as compared to CABG
treated subjects. No significant difference was found in other cases. 
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Aim: To identify factors associated with change in thrombus pattern in
STEMI patients undergoing primary PCI.
Methods: Thrombi (n=45) were obtained using the Export thromboaspira-
tion device in consecutive STEMI early presenters (<12hours from symptoms
onset) undergoing primary PCI. Ten different areas of each thrombus were
randomly scanned using a Scanning Electronic Microscope (4nm resolution).
High definition pictures (Magnification 3000X) were analysed in a blinded
way by a semi-quantitative and a visual approach to evaluate fibrin and pla-
telet content (in %). The primary endpoint was fibrin and platelet content
according to time delay from symptom onset (SO). All patients were enrolled
in the web-based registry (e-PARIS).
Results: Mean age was 59+/-14 years, 25 (83%) were male, 16 (53%) were
smoker, 12 (40%) had hypertension, 12(40%) dyslipidemia and 7(23%) were
diabetic. 4 patients (13.3%) had pre-hospital cardiac arrest and 25 patients
(83%) had a single vessel disease. All Patients received aspirin, clopidogrel,
enoxaparin or UHF and 25 (83%) received abciximab. Thrombi were com-
posed by 55.9±18% of fibrin (mean±SD), 16.8±18% of platelets, 11.5±9 % of
red cells, 5.2±8.4 % of cholesterol crystal, 1.3±2.0 % of white cells, and
2.8±3.7% mixed cell-fibrin. Median time delay from SO to PCI was (182 min
+/- 235 IQR). There was a stepwise decrease in platelet content with respect
to prolonged time delay from SO to PCI ranging from 25.6±25% in the first
tertile down to 8.7±7% in the third tertile (p=0.09) (fig.). On the other hand,
there was a stepwise increase in fibrin content ranging from 47.8±24% up to
67.3±9% (p=0.04). Analysis of other determinants of clot composition and
relation with myocardial TIMI Blush Grade is pending.
Conclusions: Platelet and fibrin content within the occlusive thrombus of
early STEMI presenters is a fast evolving process. Time delay from symptom
onset is a key determinant of thrombus composition.
Thrombus content in STEMI according ischemic time
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Acute hyperglycemia is associated with adverse outcome after pri-
mary angioplasty for acute myocardial infarction: GLAMI Study
Khaldoun Ben Hamda, Feriel Moatemri, Sonia Hamdi, Hichem Denguir,
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Hyperglycemia has been shown to be a powerful predictor of worse out-
come after ST segment-elevation myocardial infarction (STEMI).
The aim of this study was to investigate the relation between acute hypergly-
cemia (AHG) and in-hospital outcome after primary angioplasty for STEMI.
Patients and Methods: We prospectively included 250 patients who unde-
rwent revascularization with primary angioplasty for STEMI, Plasma glucose
was measured at hospital admission. Acute hyperglycemia was defined as
plasma glucose of 11 mmol/L (198 mg/dL), regardless of the diabetic status.
Results: Among the 250 patients with STEMI included in the study, 124
(49.6%) patients had acute hyperglycemia. There was no difference among the
two groups with regard to clinical characteristics except for the presence of dia-
betes (58%vs 7.1%, p<0.001), hypertension (21.4% vs 38.7%, p=0.002) and
hyperlipidemia (4.8% vs 14.5%, p=0.007. At admission, patients with AHG
were more likely to have tachycardia (26.6 % vs 14.3%, p=0.012) and to present
heart failure (24.2% vs 12.7%, p=0.01). The admission TIMI flow was similar
in the two groups. TIMI 3 flow postprocedure was more common in patients
without AHG (89.7% vs 75%, p=0.002). The in-hospital mortality rate was
significantly higher in patients with AHG than in patients without (22.6% vs
4.8%, p <0.001) . In multivariate analysis, independently of other determinants
of death ( age, risk factors, location of STEMI, infarct size, incomplete resolu-
tion of ST-segment and angiographic success), acute hyperglycemia was a pre-
dictor of in-hospital mortality ( OR: 3.14; 95% IC, 1.5-6.5; p=0.0001).
Conclusion: Acute hyperglycemia in patients with STEMI was an impor-
tant predictor of mortality, this suggest the usefulness of evaluating early gly-
cemic control in the setting of reperfusion for acute myocardial infarction.
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Benefit of Drug Eluting Stents over Bare Metal Stents after Rotatio-
nal Atherectomy. A propensity score adjusted comparison in revascu-
larization, mortality and MACE.
Francois Schiele, Kais Mrabet, Nicolas Meneveau, Marie-France Seronde,
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Bassand
CHU Besancon, Cardiologie, Besancon, France
Rationale: Rotational atherectomy makes possible to attempt small and
calcified arteries while Drug Eluting Stents (DES) properties may reduce the
restenosis process, rendering this combination attractive in selected cases. We
compared 1year clinical outcome after rotational atherectomy following by
either DES or Bare Metal Stents (BMS) implantation.
Methods: Single centre registry including all consecutive cases of rota-
tional atherectomy use. Clinical follow-up was obtained in all patients. Pro-
pensity score for being treated with a DES was calculated using 18 clinical,
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